Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer

Table 3 Progression-free survival (according to the CHAARTED and STAMPEDE definitions of progressive disease) age, PSA, comorbidities and bone metastases

	Number of patients	Number of events	HR, 95%CI, P value (univariate)	HR, 95%CI, P value (multivariate)
Age, yr (median)
≤ 68	48	21	1.00	1.00
> 68	46	15	0.78, 0.40-1.51, 0.45	0.83, 0.42-1.67, 0.61
PSA (median)
≤ 180	48	12	1.00	1.00
> 180	46	24	2.86, 1.39-5.87, 0.0041	2.51, 1.21-5.19, 0.013
Comorbidities
No	44	15	1.00	1.00
Yes	50	21	1.15, 0.59-2.23, 0.68	1.19, 0.60-2.36, 0.63
Distant metastases
No	19	3	1.00	1.00
Yes	75	33	3.36, 1.03-10.96, 0.045	2.60, 0.78-8.65, 0.12